USA: Pharma Business Deal Kal Vista Pharmaceuticals Collaborates with Merck
US-Company Kal Vista has entered into an agreement with Merck for KVD001, the company's advanced compound. As consideration for the agreement, Merck will pay to Kal Vista a $37 million non-refundable upfront fee.
Cambridge, Massachusetts/USA – Kal Vista Pharmaceuticals, a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, has recently announced that it has entered into a collaboration agreement with Merck, through a subsidiary, for KVD001. KVD001 is the company’s investigational intravitreal injection candidate currently in the development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition.
Under the terms of the agreement, Kal Vista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that Kal Vista intends to commence later this year. The company also has granted to Merck a similar option to acquire investigational orally delivered molecules for DME that Kal Vista will continue to develop as part of its ongoing research and development activities.
As consideration for the agreement, Merck will pay to Kal Vista a $37 million non-refundable upfront fee. The US-Company is further eligible to receive payments associated with the exercise of the options by Merck and the achievement of milestones for each program that potentially total up to $715 million.